Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
INO-1400 · 1 trial · 9 indications
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | 2 mg INO-1400 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12 |
| Arm 2 | EXPERIMENTAL | 8 mg INO-1400 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12 |
| Arm 3 | EXPERIMENTAL | 2 mg INO-1400 + 0.5 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12 |
| Arm 4 | EXPERIMENTAL | 2 mg INO-1400 + 2 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12 |
| Arm 5 | EXPERIMENTAL | 8 mg INO-1400 + 0.5 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12 |
| Arm 6 | EXPERIMENTAL | 8 mg INO-1400 + 2 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12 |
| Arm 7 | EXPERIMENTAL | 2 mg INO-1401 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12 |
| Arm 8 | EXPERIMENTAL | 8 mg INO-1401 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12 |
| Arm 9 | EXPERIMENTAL | 8 mg INO-1401 + 0.5 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12 |
| Arm 10 | EXPERIMENTAL | 8 mg INO-1401 + 2 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12 |
| Name | Type | Description |
|---|---|---|
| INO-1400 | BIOLOGICAL | - |
| INO-9012 | BIOLOGICAL | - |
| INO-1401 | BIOLOGICAL | - |
Inclusion Criteria: * 1\. Signed and dated written IRB approved informed consent; * 2\. Males or females aged ≥18 years; * 3\. Subjects with breast, lung or pancreatic carcinoma who are at high risk of relapse post definitive therapy at least 4 and no more than 24 weeks from completion of definitiv...
Top 20 of 92 competitors
INO-1400 is an investigational immunotherapy being studied for use in breast cancer and other solid tumors at high risk of relapse, including lung, pancreatic, head and neck, ovarian, colorectal, gastric, esophageal, and hepatocellular cancers. It is currently in Phase 1 clinical development.
INO-1400 is a monoclonal antibody designed to target hTERT, the catalytic subunit of telomerase, which is commonly expressed in cancer cells. By targeting hTERT, the therapy aims to stimulate an immune response against tumors that express this antigen.
INO-1400 is being developed by Inovio Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol INO. The company is conducting clinical research to evaluate the safety and efficacy of this investigational therapy.
INO-1400 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials to assess its safety and potential effectiveness in patients.
INO-1400 has been studied in one completed Phase 1 clinical trial, NCT02960594, which evaluated hTERT immunotherapy alone or in combination with IL-12 DNA followed by electroporation in adults with solid tumors at high risk of relapse. The trial enrolled 93 participants in the United States.
INO-1400 is an hTERT immunotherapy, and the clinical trial NCT02960594 refers to it as such. The drug targets hTERT, a protein involved in cancer cell immortality, and is being investigated for its potential to treat multiple solid tumor types.